Pharma Mar, S.A. (PHM.MC)
EUR 76.95
(0.59%)
EUR 76.95
(0.59%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.54 Million EUR | -99.25% |
| 2022 | 52.06 Million EUR | -47.76% |
| 2021 | 104.08 Million EUR | -33.44% |
| 2020 | 155.94 Million EUR | 1465.22% |
| 2019 | -11.71 Million EUR | -58.67% |
| 2018 | -9.47 Million EUR | 32.46% |
| 2017 | -12.99 Million EUR | 8.56% |
| 2016 | -12.24 Million EUR | -166.01% |
| 2015 | 14.22 Million EUR | -32.14% |
| 2014 | 26.13 Million EUR | 5.34% |
| 2013 | 24.83 Million EUR | 15.29% |
| 2012 | 21.07 Million EUR | 56.2% |
| 2011 | 13.56 Million EUR | 428.36% |
| 2010 | -3.64 Million EUR | 84.5% |
| 2009 | -15.92 Million EUR | 16.89% |
| 2008 | -36.82 Million EUR | 28.35% |
| 2007 | -40.82 Million EUR | -7.57% |
| 2006 | -42.14 Million EUR | -827.18% |
| 2005 | -33.66 Million EUR | 118.02% |
| 2004 | 293 Thousand EUR | 111.88% |
| 2003 | -22.37 Million EUR | 45.36% |
| 2002 | -40.95 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 825 Thousand EUR | 129.95% |
| 2024 Q1 | -2.81 Million EUR | 23.92% |
| 2024 Q3 | 7 Million EUR | 748.85% |
| 2023 FY | - EUR | -99.25% |
| 2023 Q1 | -1.39 Million EUR | -116.15% |
| 2023 Q2 | 5.76 Million EUR | 511.72% |
| 2023 Q3 | 469 Thousand EUR | -91.86% |
| 2023 Q4 | -3.67 Million EUR | -884.43% |
| 2022 FY | - EUR | -47.76% |
| 2022 Q1 | 23.71 Million EUR | -53.59% |
| 2022 Q3 | 12.86 Million EUR | 41.79% |
| 2022 Q2 | 9.07 Million EUR | -61.73% |
| 2022 Q4 | 8.66 Million EUR | -32.66% |
| 2021 Q3 | 5.93 Million EUR | -78.56% |
| 2021 FY | - EUR | -33.44% |
| 2021 Q1 | 19.26 Million EUR | 49.33% |
| 2021 Q2 | 27.68 Million EUR | 43.67% |
| 2021 Q4 | 51.09 Million EUR | 760.83% |
| 2020 Q2 | 46.98 Million EUR | -34.81% |
| 2020 FY | - EUR | 1465.22% |
| 2020 Q4 | 12.9 Million EUR | -46.75% |
| 2020 Q1 | 72.08 Million EUR | 3377.09% |
| 2020 Q3 | 24.23 Million EUR | -48.42% |
| 2019 Q2 | -3.18 Million EUR | 58.28% |
| 2019 Q4 | 2.07 Million EUR | 176.92% |
| 2019 Q1 | -7.63 Million EUR | 11.92% |
| 2019 FY | - EUR | -58.67% |
| 2019 Q3 | -2.69 Million EUR | 15.38% |
| 2018 Q3 | -5.31 Million EUR | -168.7% |
| 2018 Q4 | -8.66 Million EUR | -63.09% |
| 2018 FY | - EUR | 32.46% |
| 2018 Q1 | -888 Thousand EUR | 84.92% |
| 2018 Q2 | 7.73 Million EUR | 971.28% |
| 2017 Q1 | 199 Thousand EUR | 103.06% |
| 2017 Q4 | -5.88 Million EUR | -35.74% |
| 2017 Q3 | -4.33 Million EUR | -565.18% |
| 2017 FY | - EUR | 8.56% |
| 2017 Q2 | -652 Thousand EUR | -427.64% |
| 2016 Q4 | -6.5 Million EUR | -5189.43% |
| 2016 FY | - EUR | -166.01% |
| 2016 Q3 | -123 Thousand EUR | 92.68% |
| 2016 Q2 | -1.68 Million EUR | 57.25% |
| 2016 Q1 | -3.93 Million EUR | -430.14% |
| 2015 FY | - EUR | -32.14% |
| 2015 Q3 | 7.11 Million EUR | 711500.0% |
| 2015 Q1 | 9.48 Million EUR | 1832.59% |
| 2015 Q2 | -1000.00 EUR | -100.01% |
| 2015 Q4 | 1.19 Million EUR | -83.26% |
| 2014 Q4 | 491 Thousand EUR | -86.22% |
| 2014 Q2 | 2.77 Million EUR | -85.65% |
| 2014 Q1 | 19.31 Million EUR | 769.86% |
| 2014 FY | - EUR | 5.34% |
| 2014 Q3 | 3.56 Million EUR | 28.54% |
| 2013 Q2 | 2.12 Million EUR | -88.35% |
| 2013 Q1 | 18.2 Million EUR | 7037.65% |
| 2013 FY | - EUR | 15.29% |
| 2013 Q4 | 2.22 Million EUR | 0.68% |
| 2013 Q3 | 2.2 Million EUR | 4.01% |
| 2012 Q2 | 19.42 Million EUR | 670.94% |
| 2012 Q4 | 255 Thousand EUR | 124.73% |
| 2012 FY | - EUR | 56.2% |
| 2012 Q1 | -3.4 Million EUR | -115.4% |
| 2012 Q3 | -1.03 Million EUR | -105.31% |
| 2011 Q1 | -2.27 Million EUR | 66.94% |
| 2011 Q4 | 22.09 Million EUR | 1065.73% |
| 2011 FY | - EUR | 428.36% |
| 2011 Q3 | -2.28 Million EUR | -244.35% |
| 2011 Q2 | 1.58 Million EUR | 169.67% |
| 2010 FY | - EUR | 84.5% |
| 2010 Q3 | 479 Thousand EUR | -75.78% |
| 2010 Q2 | 1.97 Million EUR | 727.62% |
| 2010 Q1 | 239 Thousand EUR | 101.16% |
| 2010 Q4 | -6.88 Million EUR | -1536.53% |
| 2009 Q2 | -3.11 Million EUR | -210.37% |
| 2009 Q3 | -2.25 Million EUR | 27.69% |
| 2009 Q4 | -20.57 Million EUR | -813.86% |
| 2009 FY | - EUR | 16.89% |
| 2009 Q1 | -1 Million EUR | 91.11% |
| 2008 Q1 | -10.04 Million EUR | 0.0% |
| 2008 Q3 | -12.53 Million EUR | -3259.52% |
| 2008 FY | - EUR | 28.35% |
| 2008 Q4 | -11.27 Million EUR | 10.02% |
| 2008 Q2 | -373 Thousand EUR | 96.29% |
| 2007 FY | - EUR | -7.57% |
| 2006 FY | - EUR | -827.18% |
| 2005 FY | - EUR | 118.02% |
| 2004 FY | - EUR | 111.88% |
| 2003 FY | - EUR | 45.36% |
| 2002 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Atrys Health, S.A. | 31.91 Million EUR | 85.746% |
| Biotechnologies Assets SA | 5.09 Million EUR | 10.786% |
| Laboratorios Farmaceuticos Rovi, S.A. | 245.81 Million EUR | 98.149% |